Characterization of antitumor immunization to a defined melanoma antigen using genetically engineered murine dendritic cells

Cancer Gene Therapy

Volumn 6, Issue 6, 1999, Pages 523-536

  Ribas, Antoni ^a   Butterfield, Lisa H ^a   McBride, William H ^a   Dissette, Vivian B ^a   Koh, Andrew ^a   Vollmer, Charles M ^a   Hu, Billy ^a   Chen, Angela Y ^a   Glaspy, John A ^a   Economou, James S ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Dendritic cells; Gene therapy; Immunotherapy; In vivo animal models; Tumor immunity

Indexed keywords

MART1 ANTIGEN; TUMOR ANTIGEN; TUMOR PROTEIN;

ANIMAL; ARTICLE; C3H MOUSE; DENDRITIC CELL; DISEASE MODEL; EXPERIMENTAL MELANOMA; FEMALE; GENE THERAPY; GENETICS; IMMUNOLOGY; LUNG TUMOR; METASTASIS; MOUSE; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; ANTIGENS, NEOPLASM; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; FEMALE; GENE THERAPY; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C3H; NEOPLASM PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 0033218365     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700076     Document Type: Article

References (51)

1. Kripke ML. Antigenicity of murine skin tumors induced by ultraviolet light. J Natl Cancer Inst. 1974;53:1333-1336.
2. Speiser DE, Sebzda E, Ohteki T, et al. Tumor necrosis factor receptor p55 mediates deletion of peripheral cyto-toxic T lymphocytes in vivo. Eur J Immunol. 1996;26:3055-3060.
3. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol. 1991;9:271-296.
4. Schuler G, Steinman RM. Dendritic cells as adjuvants for immune-mediated resistance to tumors. J Exp Med. 1997; 186:1183-1187.
5. Nanda NK, Sercarz EE. Induction of anti-self-immunity to cure cancer. Cell. 1995;82:13-17.
6. Coulie PG, Brichard V, Van Pel A, et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med. 1994;180:35-42.
7. Kawakami Y, Eliyahu S, Delgado CH, et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA. 1994;91:3515-3519.
8. de Vries TJ, Fourkour A, Wobbes T, et al. Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions. Cancer Res. 1997;57: 3223-3229.
9. Ribas A, Butterfield LH, McBride WH, et al. Genetic immunization for the melanoma antigen MART-1/ Melan-A using recombinant adenovirus-transduced murine dendritic cells. Cancer Res. 1997;57:2865-2869.
10. Brossart P, Goldrath AW, Butz EA, et al. Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL. J Immunol. 1997;158:3270-3276.
11. Milas L, Wike J, Hunter N, et al. Macrophage content of murine sarcomas and carcinomas: associations with tumor growth parameters and tumor radiocurability. Cancer Res. 1987;47:1069-1075.
12. Volpe JP, Hunter N, Basic I, et al. Metastatic properties of murine sarcomas and carcinomas: positive correlation with lung colonization and lack of correlation with s.c. tumor take. Clin Exp Metastasis. 1985;3:281-294.
13. Inaba K, Inaba M, Romani N, et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med. 1992;176:1693-1702.
14. Toloza EM, Hunt K, Swisher S, et al. In vivo cancer gene therapy with a recombinant interleukin-2 adenovirus vector. Cancer Gene Ther. 1996;3:11-17.
15. Bui LA, Butterfield LH, Kim JY, et al. In vivo therapy of hepatocellular carcinoma with a tumor-specific adenoviral vector expressing interleukin-2. Hum Gene Ther. 1997;8: 2173-2182.
16. Brugert H, Kvist S. An adenovirus type 2 glycoprotein blocks cell surface expression of human histocompatibility class I antigens. Cell. 1985;41:987.
17. Lotze MT. Getting to the source: dendritic cells as therapeutic reagents for the treatment of patients with cancer. Ann Surg. 1997;226:1-5.
18. Mayordomo JI, Zorina T, Storkus WJ, et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med. 1995;1:1297-1302.
19. Mayordomo JI, Loftus DJ, Sakamoto H, et al. Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J Exp Med. 1996;183:1357-1365.
20. Porgador A, Gilboa E. Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. J Exp Med. 1995;182: 255-260.
21. Paglia P, Chiodoni C, Rodolfo M, et al. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J Exp Med. 1996;183:317-322.
22. Zitvogel L, Mayordomo JI, Tjandrawan T, et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med. 1996;183:87-97.
23. Celluzzi CM, Mayordomo JI, Storkus WJ, et al. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J Exp Med. 1996;183:283-287.
24. Boczkowski D, Nair SK, Snyder D, et al. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med. 1996;184:465-472.
25. Nair SK, Snyder D, Rouse BT, et al. Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts. Int J Cancer. 1997;70:706-715.
26. Ashley DM, Faiola B, Nair S, et al. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J Exp Med. 1997;186:1177-1182.
27. Specht JM, Wang G, Do MT, et al. Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases. J Exp Med. 1997;186:1213-1221.
28. Song W, Kong HL, Carpenter H, et al. Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity. J Exp Med. 1997;186: 1247-1256.
29. Kim CJ, Prevette T, Cormier J, et al. Dendritic cells infected with poxviruses encoding MART-1/Melan A sensitize T lymphocytes in vitro. J Immunother. 1997;20:276-286.
30. Smith CA, Woodruff LS, Kitchingman GR, et al. Adeno-virus-pulsed dendritic cells stimulate human virus-specific T-cell responses in vitro. J Virol. 1996;70:6733-6740.
31. + T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus. J Immunol. 1996;157:4079-4086.
32. van Elsas A, van der Burg SH, van der Minne CE, et al. Peptide-pulsed dendritic cells induce tumoricidal cytotoxic T lymphocytes from healthy donors against stably HLA-A*0201-binding peptides from the Melan-A/MART-1 self antigen. Eur J Immunol. 1996;26:1683-1689.
33. Van Waes C, Monach PA, Urban JL, et al. Immunodominance deters the response to other tumor antigens thereby favoring escape: prevention by vaccination with tumor variants selected with cloned cytolytic T cells in vitro. Tissue Antigens. 1996;47:399-407.
34. Jager E, Ringhoffer M, Altmannsberger M, et al. Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. Int J Cancer. 1997;71:142-147.
35. Fleischhauer K, Fruci D, Van Endert P, et al. Characterization of antigenic peptides presented by HLA-B44 molecules on tumor cells expressing the gene MAGE-3. Int J Cancer. 1996;68:622.
36. Arthur JF, Butterfield LH, Roth MD, et al. A comparison of gene transfer methods in human dendritic cells. Cancer Gene Ther. 1997;4:17-25.
37. Reeves ME, Royal RE, Lam JS, et al. Retroviral transduction of human dendritic cells with a tumor-associated antigen gene. Cancer Res. 1996;56:5672-5677.
38. Shaughnessy E, Lu D, Chatterjee S, et al. Parvoviral vectors for the gene therapy of cancer. Semin Oncol. 1996;23:159-171.
39. Zitvogel L, Couderc B, Mayordomo JI, et al. IL-12-engineered dendritic cells serve as effective tumor vaccine adjuvants in vivo. Ann N Y Acad Sci. 1996;795:284-293.
40. Carter LL, Dutton RW. Relative perforin- and Fas-mediated lysis in T1 and T2 CD8 effector populations. J Immunol. 1995;155:1028-1031.
41. + T helper cell phenotype development in a T cell receptor-αβ-transgenic model. J Exp Med. 1995;182:1579-1584.
42. Scott DW, Grdina T, Shi Y. T cells commit suicide, but B cells are murdered! J Immunol. 1996;156:2352.
43. Green DR, Scott DW. Activation-induced apoptosis in lymphocytes. Curr Opin Immunol. 1994;6:476-487.
44. Barratt-Boyes SM, Watkins SC, Finn OJ. In vivo migration of dendritic cells differentiated in vitro: a chimpanzee model. J Immunol. 1997;158:4543.
45. Kupiec-Weglinski JW, Austyn JM, Morris PJ. Migration patterns of dendritic cells in the mouse: traffic from the blood, and T cell-dependent and -independent entry to lymphoid tissues. J Exp Med. 1988;167:632.
46. Inaba K, Steinman RM, Pack MW, et al. Identification of proliferating dendritic cell precursors in mouse blood. J Exp Med. 1992;175:1157-1167.
47. Mayordomo JI, Zorina T, Storkus WJ, et al. Bone marrow-derived dendritic cells serve as potent adjuvants for peptide-based antitumor vaccines. Stem Cells. 1997;15:94-103.
48. Hagenbaugh A, Sharma S, Dubinett SM, et al. Altered immune responses in interleukin 10 transgenic mice. J Exp Med. 1997;185:2101-2110.
49. Butterfield LH, Jilani SM, Chakraborty NG, et al. Generation of melanoma-specific CTLs by dendritic cells transduced with a MART-1 adenovirus. J Immunol. 1998;161: 5607-5613.
50. + T cell responses to dendritic cells genetically engineered to express the MART-1/Melan-A gene. Cancer Res. 1998;58:5305-5309.
51. Zhai Y, Yang JC, Spiess P, et al. Cloning and characterization of the genes encoding the murinc homologues of the human melanoma antigens MART1 and gp100. J Immunother. 1997;20:15-25.